Company intelligence / Profile preview
Immunome
Exton, Pennsylvania, United Statesimmunome.com ↗
- Ownership
- Public · IMNM
- Employees
- ~11
- Development stage
- Phase 1
01
Overview
Immunome has advanced to the clinical stage with a pipeline of targeted cancer therapies. Their approach leverages patient-derived immune responses to discover novel antigens and corresponding antibodies. The company’s lead programs include antibody-drug conjugates (ADCs) and other immunotherapies targeting difficult-to-treat cancers. Detailed clinical results are not specified in public summaries as of June 2025
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyRadioligand therapyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Financials
- Market cap
- $2.1B
- Total revenue
- $6.9M
- Enterprise value
- $1.6B
Beyond the preview
Go deeper on Immunome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunome.